SE538503C2 - New dextran sulfate - Google Patents
New dextran sulfate Download PDFInfo
- Publication number
- SE538503C2 SE538503C2 SE1451349A SE1451349A SE538503C2 SE 538503 C2 SE538503 C2 SE 538503C2 SE 1451349 A SE1451349 A SE 1451349A SE 1451349 A SE1451349 A SE 1451349A SE 538503 C2 SE538503 C2 SE 538503C2
- Authority
- SE
- Sweden
- Prior art keywords
- dextran sulfate
- dextran
- interval
- average
- sulfate
- Prior art date
Links
- 229960000633 dextran sulfate Drugs 0.000 title claims description 210
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 59
- 230000019635 sulfation Effects 0.000 claims description 54
- 238000005670 sulfation reaction Methods 0.000 claims description 54
- 238000005481 NMR spectroscopy Methods 0.000 claims description 44
- 150000003839 salts Chemical class 0.000 claims description 30
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 27
- 150000002500 ions Chemical class 0.000 claims description 7
- 159000000000 sodium salts Chemical class 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 2
- 238000004611 spectroscopical analysis Methods 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 description 43
- 229960002086 dextran Drugs 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000000126 substance Substances 0.000 description 26
- 238000000034 method Methods 0.000 description 21
- 241000700159 Rattus Species 0.000 description 15
- 201000002491 encephalomyelitis Diseases 0.000 description 15
- 230000004071 biological effect Effects 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000001228 spectrum Methods 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000000149 argon plasma sintering Methods 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 230000037396 body weight Effects 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 8
- 238000000990 heteronuclear single quantum coherence spectrum Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 8
- 238000001556 precipitation Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 238000001542 size-exclusion chromatography Methods 0.000 description 8
- 238000007920 subcutaneous administration Methods 0.000 description 8
- 230000001186 cumulative effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 238000005227 gel permeation chromatography Methods 0.000 description 7
- 238000011081 inoculation Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 6
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 229960002303 citric acid monohydrate Drugs 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000010253 intravenous injection Methods 0.000 description 5
- 229960001412 pentobarbital Drugs 0.000 description 5
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- -1 0.9 % NaCI saline Chemical compound 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000005570 heteronuclear single quantum coherence Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000001483 mobilizing effect Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Chemical compound O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 4
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 3
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 3
- 238000005084 2D-nuclear magnetic resonance Methods 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 238000012565 NMR experiment Methods 0.000 description 2
- 238000011887 Necropsy Methods 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000008366 buffered solution Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000498 cooling water Substances 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 230000003595 spectral effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 238000001370 static light scattering Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001180 sulfating effect Effects 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000004340 gradient COSY Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229920006158 high molecular weight polymer Polymers 0.000 description 1
- 201000008298 histiocytosis Diseases 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 238000000569 multi-angle light scattering Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000005016 nuclear Overhauser enhanced spectroscopy Methods 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- YALHCTUQSQRCSX-UHFFFAOYSA-N sulfane sulfuric acid Chemical compound S.OS(O)(=O)=O YALHCTUQSQRCSX-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000011191 terminal modification Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000002495 two-dimensional nuclear magnetic resonance spectrum Methods 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/02—Dextran; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (31)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451349A SE538503C2 (sv) | 2014-11-11 | 2014-11-11 | New dextran sulfate |
| EA201790856A EA032383B1 (ru) | 2014-11-11 | 2015-11-10 | Новый сульфат декстрана |
| SI201530562T SI3217988T1 (sl) | 2014-11-11 | 2015-11-10 | Novi dekstran sulfat |
| TR2019/00334T TR201900334T4 (tr) | 2014-11-11 | 2015-11-10 | Yeni Dekstran Sülfat |
| LTEP15858497.9T LT3217988T (lt) | 2014-11-11 | 2015-11-10 | Naujasis dekstrano sulfatas |
| CN201580061059.4A CN107106595B (zh) | 2014-11-11 | 2015-11-10 | 新型硫酸葡聚糖 |
| MX2017006122A MX364314B (es) | 2014-11-11 | 2015-11-10 | Nuevo sulfato de dextrano. |
| JP2017525349A JP6251459B1 (ja) | 2014-11-11 | 2015-11-10 | 新規なデキストラン硫酸 |
| CA2967264A CA2967264C (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| KR1020177013121A KR101834710B1 (ko) | 2014-11-11 | 2015-11-10 | 신규한 덱스트란 설페이트 |
| MYPI2017701627A MY181598A (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| RS20190040A RS58222B1 (sr) | 2014-11-11 | 2015-11-10 | Novi dekstran sulfat |
| PL15858497T PL3217988T3 (pl) | 2014-11-11 | 2015-11-10 | Nowy siarczan dekstranu |
| AU2015347361A AU2015347361B2 (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| NZ731141A NZ731141A (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| SG11201703198PA SG11201703198PA (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| PT15858497T PT3217988T (pt) | 2014-11-11 | 2015-11-10 | Novo sulfato de dextrano |
| HRP20190073TT HRP20190073T1 (hr) | 2014-11-11 | 2015-11-10 | Novi dekstran sulfat |
| HUE15858497A HUE042806T2 (hu) | 2014-11-11 | 2015-11-10 | Új dextrán-szulfát |
| US15/525,818 US10407514B2 (en) | 2014-11-11 | 2015-11-10 | Dextran sulfate |
| PCT/SE2015/051188 WO2016076780A1 (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| DK15858497.9T DK3217988T3 (en) | 2014-11-11 | 2015-11-10 | HOW TO UNKNOWN DEXTRANSULPHATE |
| EP15858497.9A EP3217988B1 (en) | 2014-11-11 | 2015-11-10 | New dextran sulfate |
| ES15858497T ES2706287T3 (es) | 2014-11-11 | 2015-11-10 | Sulfato de dextrano nuevo |
| BR112017009752-4A BR112017009752B1 (pt) | 2014-11-11 | 2015-11-10 | Sulfato de dextrano |
| SM20190032T SMT201900032T1 (it) | 2014-11-11 | 2015-11-10 | Nuovo solfato di destrano |
| IL251871A IL251871A (en) | 2014-11-11 | 2017-04-23 | Dextran sulfate has enhanced biological properties |
| PH12017500799A PH12017500799B1 (en) | 2014-11-11 | 2017-04-27 | New dextran sulfate |
| SA517381478A SA517381478B1 (ar) | 2014-11-11 | 2017-05-07 | كبريتات ديكستران لها تأثيرات بيولوجية محسنة |
| CY20191100024T CY1121336T1 (el) | 2014-11-11 | 2019-01-10 | Νεα θειικη δεξτρανη |
| US16/520,930 US10730960B2 (en) | 2014-11-11 | 2019-07-24 | Dextran sulfate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1451349A SE538503C2 (sv) | 2014-11-11 | 2014-11-11 | New dextran sulfate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE1451349A1 SE1451349A1 (sv) | 2016-05-12 |
| SE538503C2 true SE538503C2 (sv) | 2016-08-16 |
Family
ID=55954726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE1451349A SE538503C2 (sv) | 2014-11-11 | 2014-11-11 | New dextran sulfate |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10407514B2 (sv) |
| EP (1) | EP3217988B1 (sv) |
| JP (1) | JP6251459B1 (sv) |
| KR (1) | KR101834710B1 (sv) |
| CN (1) | CN107106595B (sv) |
| AU (1) | AU2015347361B2 (sv) |
| BR (1) | BR112017009752B1 (sv) |
| CA (1) | CA2967264C (sv) |
| CY (1) | CY1121336T1 (sv) |
| DK (1) | DK3217988T3 (sv) |
| EA (1) | EA032383B1 (sv) |
| ES (1) | ES2706287T3 (sv) |
| HR (1) | HRP20190073T1 (sv) |
| HU (1) | HUE042806T2 (sv) |
| IL (1) | IL251871A (sv) |
| LT (1) | LT3217988T (sv) |
| MX (1) | MX364314B (sv) |
| MY (1) | MY181598A (sv) |
| NZ (1) | NZ731141A (sv) |
| PH (1) | PH12017500799B1 (sv) |
| PL (1) | PL3217988T3 (sv) |
| PT (1) | PT3217988T (sv) |
| RS (1) | RS58222B1 (sv) |
| SA (1) | SA517381478B1 (sv) |
| SE (1) | SE538503C2 (sv) |
| SG (1) | SG11201703198PA (sv) |
| SI (1) | SI3217988T1 (sv) |
| SM (1) | SMT201900032T1 (sv) |
| TR (1) | TR201900334T4 (sv) |
| WO (1) | WO2016076780A1 (sv) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018212708A1 (en) | 2017-05-17 | 2018-11-22 | Tx Medic Ab | Treatment of glaucoma |
| PL3532072T3 (pl) | 2017-05-17 | 2020-09-21 | Tx Medic Ab | Leczenie jaskry |
| EP3678675B1 (en) * | 2017-09-08 | 2024-11-20 | TX Medic AB | New use of dextran sulfate |
| CN113286827A (zh) * | 2018-06-20 | 2021-08-20 | 营养与生物科学美国第四公司 | 多糖衍生物和包含其的组合物 |
| SE543275C2 (sv) * | 2019-03-07 | 2020-11-10 | Tx Medic Ab | Treatment efficiency evaluation |
| SE544015C2 (en) * | 2019-06-18 | 2021-11-02 | Tx Medic Ab | Allogenic car-t cell therapy |
| US20230346827A1 (en) * | 2020-04-15 | 2023-11-02 | Tx Medic Ab | Treatment of coronavirus infections |
| GB202008919D0 (en) | 2020-06-11 | 2020-07-29 | Univ Birmingham | Polysaccharide conpositions and therapeutic gels |
| SE544447C2 (en) * | 2020-09-29 | 2022-05-31 | Tx Medic Ab | Treatment of fatty liver diseases |
| EP4225327A4 (en) | 2020-10-09 | 2024-10-16 | TX Medic AB | TREATMENT OF MUSCLE ATROPHY WITH DEXTRAN SULFATE |
| US20240189343A1 (en) * | 2021-04-14 | 2024-06-13 | Tx Medic Ab | Treatment of virus infections |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3141014A (en) | 1960-03-31 | 1964-07-14 | Meito Sangyo Kk | Sodium and potassium salts of the dextran sulphuric acid ester having substantially no anticoagulant activity but having lipolytic activity and the method of preparation thereof |
| JPS4730167Y1 (sv) | 1967-03-09 | 1972-09-09 | ||
| JPS469570Y1 (sv) | 1968-08-28 | 1971-04-05 | ||
| US4232150A (en) * | 1979-07-09 | 1980-11-04 | American Cyanamid Company | Oligosaccharide precursors to substituted O-α-D and O-β-D-multigalactopyranosyl and glucopyranosyl 1→4 and 1→6 galactopyranosyl 1→6α-D-glucopyranoses |
| US4221907A (en) * | 1979-07-09 | 1980-09-09 | American Cyanamid Company | Substituted O-α-D and O-β-D-multi-galactopyranosyl and glucopyranosyl 1→4 and 1→6 galactopyranosyl 1→6 α-D-glucopyranoses |
| US4855416A (en) * | 1983-07-25 | 1989-08-08 | Polydex Pharmaceuticals, Ltd | Method for the manufacture of dextran sulfate and salts thereof |
| EP0240098A3 (en) | 1986-04-04 | 1989-05-10 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Oligo and polysaccharides for the treatment of diseases caused by retroviruses |
| IL79254A0 (en) | 1986-06-26 | 1986-09-30 | Hadassah Med Org | Compositions for preventing graft rejection |
| IL88554A0 (en) | 1988-12-01 | 1989-07-31 | Hadassah Med Org | Compositions containing a compound binding to a heparin receptor |
| TW318142B (sv) | 1991-06-03 | 1997-10-21 | Mitsubishi Chemicals Co Ltd | |
| US5464815A (en) | 1993-09-08 | 1995-11-07 | Genentech, Inc. | Inhibition of heparin-binding |
| JPH08301771A (ja) | 1995-03-08 | 1996-11-19 | Shiseido Co Ltd | 腎疾患の予防または治療用製剤 |
| AUPN261895A0 (en) * | 1995-04-28 | 1995-05-18 | Australian National University, The | Preparation and use of sulfated oligosaccharides |
| FR2772382B1 (fr) | 1997-12-11 | 2000-03-03 | Solutions | Derives de dextrane, leur procede de preparation et leurs applications comme medicaments a action biologique specifique |
| JP2000178196A (ja) * | 1998-12-11 | 2000-06-27 | Seikagaku Kogyo Co Ltd | 新規ヒアルロニダーゼ阻害剤及び外用剤 |
| CN1347919A (zh) | 2000-10-12 | 2002-05-08 | 中国科学院生态环境研究中心 | 带有支链的硫酸酯化寡糖的制备 |
| FR2832708B1 (fr) | 2001-11-29 | 2004-02-13 | Organes Tissus Regeneration Re | Procede de sulfonation de composes comprenant des groupements hydroxyle (oh) libres ou des amines primaires ou secondaires |
| US20040009953A1 (en) | 2002-01-10 | 2004-01-15 | Comper Wayne D. | Antimicrobial charged polymers that exhibit resistance to lysosomal degradation during kidney filtration and renal passage, compositions and method of use thereof |
| SE525461C3 (sv) | 2002-11-28 | 2005-03-23 | Prophymed Ab | Ny användning av dextransulfat |
| WO2008153962A2 (en) | 2007-06-08 | 2008-12-18 | The Trustees Of The University Of Pennylvania | Method of reducing tissue loss in pancreatic islet cell transplantation |
| SG2014006985A (en) | 2009-02-02 | 2014-04-28 | Otsuka Pharma Co Ltd | Low-molecular polysulfated hyaluronic acid derivative and medicine containing same |
| SE537742C2 (sv) | 2013-05-13 | 2015-10-13 | Tx Medic Ab | Dextransulfat för cellmobilisering |
| CN103554297B (zh) | 2013-10-21 | 2016-09-07 | 兰州大学 | 一种高硫代度红芪多糖硫酸酯的制备方法及其应用 |
| SG11201610142PA (en) * | 2014-06-12 | 2017-01-27 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
-
2014
- 2014-11-11 SE SE1451349A patent/SE538503C2/sv not_active IP Right Cessation
-
2015
- 2015-11-10 MX MX2017006122A patent/MX364314B/es active IP Right Grant
- 2015-11-10 PT PT15858497T patent/PT3217988T/pt unknown
- 2015-11-10 MY MYPI2017701627A patent/MY181598A/en unknown
- 2015-11-10 CN CN201580061059.4A patent/CN107106595B/zh active Active
- 2015-11-10 EA EA201790856A patent/EA032383B1/ru not_active IP Right Cessation
- 2015-11-10 SM SM20190032T patent/SMT201900032T1/it unknown
- 2015-11-10 JP JP2017525349A patent/JP6251459B1/ja active Active
- 2015-11-10 PL PL15858497T patent/PL3217988T3/pl unknown
- 2015-11-10 CA CA2967264A patent/CA2967264C/en active Active
- 2015-11-10 US US15/525,818 patent/US10407514B2/en active Active
- 2015-11-10 LT LTEP15858497.9T patent/LT3217988T/lt unknown
- 2015-11-10 TR TR2019/00334T patent/TR201900334T4/tr unknown
- 2015-11-10 SI SI201530562T patent/SI3217988T1/sl unknown
- 2015-11-10 NZ NZ731141A patent/NZ731141A/en unknown
- 2015-11-10 HR HRP20190073TT patent/HRP20190073T1/hr unknown
- 2015-11-10 SG SG11201703198PA patent/SG11201703198PA/en unknown
- 2015-11-10 ES ES15858497T patent/ES2706287T3/es active Active
- 2015-11-10 HU HUE15858497A patent/HUE042806T2/hu unknown
- 2015-11-10 DK DK15858497.9T patent/DK3217988T3/en active
- 2015-11-10 KR KR1020177013121A patent/KR101834710B1/ko active Active
- 2015-11-10 BR BR112017009752-4A patent/BR112017009752B1/pt active IP Right Grant
- 2015-11-10 RS RS20190040A patent/RS58222B1/sr unknown
- 2015-11-10 EP EP15858497.9A patent/EP3217988B1/en active Active
- 2015-11-10 WO PCT/SE2015/051188 patent/WO2016076780A1/en not_active Ceased
- 2015-11-10 AU AU2015347361A patent/AU2015347361B2/en active Active
-
2017
- 2017-04-23 IL IL251871A patent/IL251871A/en active IP Right Grant
- 2017-04-27 PH PH12017500799A patent/PH12017500799B1/en unknown
- 2017-05-07 SA SA517381478A patent/SA517381478B1/ar unknown
-
2019
- 2019-01-10 CY CY20191100024T patent/CY1121336T1/el unknown
- 2019-07-24 US US16/520,930 patent/US10730960B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10730960B2 (en) | Dextran sulfate | |
| DK173818B1 (da) | Heparinderivat | |
| Santos et al. | Structural and functional analyses of bovine and porcine intestinal heparins confirm they are different drugs | |
| Pomin et al. | Residual keratan sulfate in chondroitin sulfate formulations for oral administration | |
| UA127034C2 (uk) | Композиція мануронової дикарбонової кислоти | |
| JP6511418B2 (ja) | 高純度ヘパリンおよびその製造方法 | |
| ZA200208299B (en) | Polysaccharidic esters of N-derivatives of glutamic acid. | |
| Li et al. | Antioxidant, anticoagulant and thrombolytic properties of SIP-IV, a sulfated polysaccharide from Sepia esculenta ink, and its derivatives | |
| JPS6322801A (ja) | Ｅｄｔａ不含のヘパリン、ヘパリン分画ならびに断片、それらの製造法及びそれらを含有する医薬品組成物 | |
| DE69413467T2 (de) | Polyglucuronsäure als remittierendes Mittel für das nephrotische Syndrom und Symptome von Hepatopathie | |
| JP2001240607A (ja) | ヘパリン解重合法、解重合ヘパリン、その誘導体および医薬組成物 | |
| CN102247401A (zh) | 低分子量糖基化硫酸软骨素及其在抗hiv-1药物制备中的用途 | |
| HK1236399A1 (en) | New dextran sulfate | |
| HK1236399B (zh) | 新型硫酸葡聚糖 | |
| Sun et al. | PEGylated inulin as long-circulating pharmaceutical carrier | |
| AU2015203727B2 (en) | High Purity Heparin and Production Method Therefor | |
| CN120795196A (zh) | 一种用于肺部靶向的红花多糖及其制备方法和应用 | |
| CN119954985A (zh) | 化学修饰的糖胺聚糖及其制备方法和用途 | |
| BR112020010887B1 (pt) | Pentosano polissulfato, medicamento, agente tampão de ph, e, uso de pentosano polissulfato, de um sal farmaceuticamente aceitável do mesmo ou de um solvato farmaceuticamente aceitável do pentosano polissulfato ou do sal farmaceuticamente aceitável do mesmo | |
| HK40050737B (en) | High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |